Clinical trials: Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated.
- Trial name
- SKYLINE (NCT06104319)
- Testing
- GSK4532990
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Fatty Liver
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
The purpose of this study is to assess the effect of Rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH).
- Trial name
- NCT00576667
- Testing
- Rimonabant
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 165 people
- Sponsor
- Sanofi
COVID-19
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
- Trial name
- COVERSCAN (NCT04369807)
- Testing
- Outpatient MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 693 people
- Sponsor
- Perspectum
Fatty Liver
Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)
Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal liver tests. It is closely linked to health problems like obesity and diabetes.
- Trial name
- NCT02363309
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver, Insulin Resistance
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin…
- Trial name
- NCT00252499
- Testing
- rosiglitazone, fenofibrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Non-Alcoholic Fatty Liver Disease
Effect of Molecular Hydrogen in Patients With NAFLD
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective…
- Trial name
- EMoHyNAFLD (NCT05325398)
- Testing
- HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
- Where
- Slovakia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Comenius University
Non-Alcoholic Fatty Liver Disease, Obese
Fatty Liver in Obesity: Long-lifestyle Follow-up (FLiO)
Non-alcoholic fatty liver disease (NAFLD) is a condition of excessive hepatic lipid accumulation in subjects that consume less than 20g ethanol per day, without other known causes as drugs consumption or toxins exposure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obese, Overweight
- Trial name
- FLiO (NCT03183193)
- Testing
- Control diet, FLiO diet
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Total Pancreatectomy, Pancreaticoduodenectomy
Hepatic Histology and Metabolism Following Total Pancreatectomy and Pancreaticoduodenectomy
The objective of the study is to investigate the development of NAFLD following total pancreatectomy and pancreaticoduodenectomy and to explore the histological and metabolic changes following the procedures.
- Conditions
- Total Pancreatectomy, Pancreaticoduodenectomy, Pancreatic Diabetes, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03864744
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Steno Diabetes Center Copenhagen
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Ultrasound and Attenuation Imaging
Fatty liver disease affects almost a 3rd of the United Kingdom (UK) population. Currently, this is being investigated using a type of MRI scan that reports how fatty or not a person's liver is, with a liver fat score, but many…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis, Steatosis of Liver
- Trial name
- NCT06552377
- Testing
- Ultrasound Attenuation imaging measurement
- Where
- United Kingdom
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Hywel Dda Health Board
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity.
- Trial name
- AdipoDROMExpo (NCT07330830)
- Where
- 3 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied.
- Trial name
- CERADIAB (NCT03447964)
- Testing
- dosing of sphingolipids
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Non-alcoholic Fatty Liver Disease, Chronic Kidney Disease
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease
The present study investigates relationship between non-alcoholic fatty liver disease and its risk factors, such as genetic background and diseases, such as chronic kidney disease and diabetes mellitus.
- Conditions
- Non-alcoholic Fatty Liver Disease, Chronic Kidney Disease, Diabetes Mellitus
- Trial name
- NAFLDDMCKD (NCT02947568)
- Testing
- non-interventional study
- Where
- Hungary
- Volunteers
- 600 people
- Sponsor
- University of Pecs
Obesity, NAFLD
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome
Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components, with secondary beneficial…
- Conditions
- Obesity, NAFLD, Fatty Liver, Pre Diabetes
- Trial name
- CALIBRATE (NCT04786418)
- Testing
- Standard of care, Low-calorie diet
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study
This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease…
- Trial name
- NCT04800094
- Testing
- Investigational Liver Fat Quantification Software
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Metabolic- Associated Fatty Liver Disease (MAFLD)
MAFLD Fibrosis Score for Detecting Fibrotic NASH in MAFLD Egyptian Patients
Metabolic-associated fatty liver disease (MAFLD), is a metabolic stress-induced liver injury characterized by diffuse hepatocyte macrovesicular fatty infiltration.
- Trial name
- NCT06492369
- Where
- Egypt
- Volunteers
- 382 people
- Sponsor
- Tanta University
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Nonalcoholic Fatty Liver Disease
Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg
The aim of the present study is to assess, by using a simple algorithm combining FIB-4 and Fibroscan, the prevalence of NASH with advanced fibrosis in outpatients followed in various hospital specialty clinics other than…
- Trial name
- NASH-SPE (NCT04282447)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Strasbourg, France
Non-alcoholic Steatohepatitis (NASH)
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05423327
- Testing
- No Intervention
- Where
- 50 sites in United States, Brazil and 3 more
- Volunteers
- 5,311 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Alcoholic Fatty Liver Disease, Type2diabetes
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM.
- Trial name
- NCT05942963
- Testing
- Empagliflozin 10 MG, Pioglitazone 15mg, Metformin
- Where
- Pakistan
- Volunteers
- 240 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Non-alcoholic Steatohepatitis
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.
- Trial name
- NCT05668936
- Testing
- Cotadutide, Moxifloxacin
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.